Ozdede, Ayse http://orcid.org/0000-0002-6531-8138
Guner, Sabriye http://orcid.org/0000-0002-9582-8374
Ozcifci, Guzin http://orcid.org/0000-0002-4774-9284
Yurttas, Berna http://orcid.org/0000-0002-6096-0340
Toker Dincer, Zeynep http://orcid.org/0000-0002-0762-7725
Atli, Zeynep http://orcid.org/0000-0002-2959-0978
Uygunoğlu, Uğur http://orcid.org/0000-0003-2866-4004
Durmaz, Eser http://orcid.org/0000-0002-1468-0153
Uçar, Didar http://orcid.org/0000-0002-3469-7307
Uğurlu, Serdal http://orcid.org/0000-0002-9561-2282
Saip, Sabahattin http://orcid.org/0000-0002-2802-7227
Tabak, Fehmi http://orcid.org/0000-0001-8632-2825
Hamuryudan, Vedat http://orcid.org/0000-0001-6625-1652
Seyahi, Emire http://orcid.org/0000-0003-4965-2918
Article History
Received: 21 February 2022
Accepted: 16 March 2022
First Online: 4 April 2022
Declarations
:
: Ayse Ozdede, Sabriye Guner, Guzin Ozcifci, Berna Yurttas, Zeynep Toker Dincer, Zeynep Atli, Ugur Uygunoglu, Eser Durmaz, Didar Ucar, Sabahattin Saip, and Vedat Hamuryudan declare that they have no conflict of interest. Serdal Ugurlu has received honoraria, consulting or speaker fees from Novartis, Pfizer, Lilly and Celltrion. Fehmi Tabak, has received honoraria, consulting or speaker fees from GSK, MSD, AbbVie and Gilead. Emire Seyahi has received honoraria, consulting or speaker fees from Novartis, Pfizer, AbbVie and Gilead.
Free to read: This content has been made available to all.